Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director | June 29, 2017 | July 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date June 29, 2017 · Filed July 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Esperante Holding NV | 1,064,338 |
Last balance in matching sequence
After 2017-06-29 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-29 · Sale · Disposed 229,138 · Balance 1,085,200 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein). F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 - $26.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Row 2 · 2017-06-29 · Sale · Disposed 20,862 · Balance 1,064,338 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein). F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 - $27.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. F3: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein).
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 - $26.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 - $27.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 29, 2017 Filed Jul 3, 2017 21:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 20,862 | $26.58 | $554,511.96 |
DisclosureSEC source: 0001209191-17-042886 · doc4.xml · nonDerivative · entry 2 Slagel Dean · CIK 0001597359 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Esperante Holding NV Disclosed balance after: 1,064,338 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 - $27.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. F3 · ownership.nature: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 29, 2017 Filed Jul 3, 2017 21:53 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 229,138 | $25.81 | $5,914,051.78 |
DisclosureSEC source: 0001209191-17-042886 · doc4.xml · nonDerivative · entry 1 Slagel Dean · CIK 0001597359 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Esperante Holding NV Disclosed balance after: 1,085,200 F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Esperante Holding NV on June 14, 2017 (See Footnote 3 herein). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.47 - $26.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F3 · ownership.nature: These shares are owned by Esperante Holding NV. The Reporting Person is a director of the Issuer and the Managing Director of Esperante BV, a wholly-owned subsidiary of Esperante Holding NV. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 21, 2017 Filed Jun 23, 2017 22:36 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $19.50 | $0.00 |
DisclosureSEC source: 0001209191-17-041750 · doc4.xml · derivative · entry 1 Slagel Dean · CIK 0001597359 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: This option was granted to the reporting person pursuant to the issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on June 21, 2018, subject to the reporting person's continued service as a director through such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.